文章名稱引用次數

• Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes77
• Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes33
• Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer32
• Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer31
• Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies27
• Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)26
• Strategies to Address Chimeric Antigen Receptor Tonic Signaling23
• MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma22
• Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors21
• We're Not DON Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine20